Acer Therapeutics Inc (NASDAQ:ACER)
| 0.75 Delayed Data As of Mar 24 |  -0.022 / -2.85%Today’s Change | 0.65 Today|||52-Week Range 4.56 | -70.12% Year-to-Date |
Latest ACER News | Press Releases
| ACER's Stock Down on Failure of Phase II Study, Cash Updates Mar 20 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 0.77 |
| Today’s open | 0.76 |
| Day’s range | 0.75 - 0.76 |
| Volume | 353 |
| Average volume (3 months) | 583,350 |
| Market cap | $11.0M |
Data as of 3:52pm ET, 03/24/2023
Growth & Valuation
| Earnings growth (last year) | +47.64% |
| Earnings growth (this year) | -37.04% |
| Earnings growth (next 5 years) | +10.50% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | 25.82 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| NRBONeurobo Pharmaceutic... | -0.01 | -1.49% |
| ---- | ||
| --Kyto Technology and ... | 0.00 | 0.00% |
| ---- |
Data as of 3:14pm ET, 03/24/2023
Financials
| Next reporting date | March 27, 2023 |
| EPS forecast (this quarter) | -$0.37 |
| Annual revenue (last year) | $1.3M |
| Annual profit (last year) | -$15.4M |
| Net profit margin | -1,220.16% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Newton, Massachusetts |
Forecasts
